Stay updated with breaking news from Group Efficacy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In patients with STEMI and multivessel disease, FFR-guided complete nonculprit revascularization did not reduce events vs culprit lesion-only PCI in the FULL-REVASC trial.
MHRA today granted a licence for Ongavia (ranibizumab), a biosimilar to Lucentis*, for the treatment of (wet) age-related macular degeneration (AMD) and several other eye diseases, such as diabetic